MedPath

Prandial Orientated Biphasic Insulin Aspart 30 Therapy - the Physiological Premix Insulin Therapy for Type 2 Diabetes

Completed
Conditions
Diabetes
Diabetes Mellitus, Type 2
Interventions
Registration Number
NCT01536652
Lead Sponsor
Novo Nordisk A/S
Brief Summary

This study is conducted in Europe. The aim of this observational study is to document the glycaemic parameters, adverse events, including drug reactions, as well as hypoglycaemic episodes, in patients that switched from insulin glargine combined with oral antidiabetic drugs (OADs) to biphasic insulin aspart 30 (NovoMix® 30) combined with OADs, when applicable.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
4994
Inclusion Criteria
  • Subjects with diabetes mellitus type 2
Read More
Exclusion Criteria

Not provided

Read More

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
BIAsp 30 usersbiphasic insulin aspart 30-
Primary Outcome Measures
NameTimeMethod
HbA1c (glycosylated haemoglobin)
Secondary Outcome Measures
NameTimeMethod
Insulin dosage
Incidence of (serious) adverse drug reactions
Incidence of hypoglycaemic episodes
Body weight
Preprandial and postprandial blood glucose values (self measured)
© Copyright 2025. All Rights Reserved by MedPath